A fully-automated one-pot synthesis of [18F]fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F]fluoromethyl tosylate

被引:24
作者
Rodnick, Melissa E. [1 ]
Brooks, Allen F. [1 ]
Hockley, Brian G. [1 ]
Henderson, Bradford D. [1 ]
Scott, Peter J. H. [1 ,2 ]
机构
[1] Univ Michigan, Sch Med, Div Nucl Med, Dept Radiol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Interdept Program Med Chem, Ann Arbor, MI 48109 USA
关键词
F-18]fluoromethylcholine; Prostate cancer imaging; Positron emission tomography; Fluorine-(18); CHOLINE; TRANSPORT;
D O I
10.1016/j.apradiso.2013.04.017
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Introduction: A novel one-pot method for preparing [F-18]fluoromethylcholine ([F-18]FCH) via in situ generation of [F-18]fluoromethyl tosylate ([F-18]FCH2OTs), and subsequent [F-18]fluoromethylation of dimethylaminoethanol (DMAE), has been developed. Methods: [F-18]FCH was prepared using a GE TRACERlab FXFN, although the method should be readily adaptable to any other fluorine-(18) synthesis module. Initially ditosylmethane was fluorinated to generate [F-18]FCH2OTs. DMAE was then added and the reaction was heated at 120 degrees C for 10 min to generate [F-18]FCH. After this time, reaction solvent was evaporated, and the crude reaction mixture was purified by solid-phase extraction using C-18-Plus and CM-Light Sep-Pak cartridges to provide [F-18]FCH formulated in USP saline. The formulated product was passed through a 0.22 mu m filter into a sterile dose vial, and submitted for quality control testing. Total synthesis time was 1.25 h from end-of-bombardment. Results: Typical non-decay-corrected yields of [F-18]FCH prepared using this method were 91 mCi (7% non-decay corrected based upon similar to 13 Ci [F-18]fluoride), and doses passed all other quality control (QC) tests. Conclusion: A one-pot liquid-phase synthesis of [F-18]FCH has been developed. Doses contain extremely low levels of residual DMAE (31.6 mu g/10 mL dose or similar to 3 ppm) and passed all other requisite QC testing, confirming their suitability for use in clinical imaging studies. (c) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 28 条
[1]  
Aboagye E.O., 2012, NOVEL RADIOTRACER, P70
[2]   18F-fluorocholine for prostate cancer imaging: a systematic review of the literature [J].
Bauman, G. ;
Belhocine, T. ;
Kovacs, M. ;
Ward, A. ;
Beheshti, M. ;
Rachinsky, I. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) :45-55
[3]   Management of recurrent disease after radical prostatectomy [J].
Bott, SRJ .
PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (03) :211-216
[4]   Imaging prostate cancer: An update on positron emission tomography and magnetic resonance imaging [J].
Bouchelouche K. ;
Turkbey B. ;
Choyke P. ;
Capala J. .
Current Urology Reports, 2010, 11 (3) :180-190
[5]  
Chi D.Y., 2006, Method for the Preparation of Organofluoro Compounds in Alchohol Solvents, Patent No. [WO 2006/065038 Al, 20061065038]
[6]   CARRIER MEDIATED BLOOD-BRAIN-BARRIER TRANSPORT OF CHOLINE AND CERTAIN CHOLINE ANALOGS [J].
CORNFORD, EM ;
BRAUN, LD ;
OLDENDORF, WH .
JOURNAL OF NEUROCHEMISTRY, 1978, 30 (02) :299-308
[7]  
DeGrado T.R., 2001, 18F-Labeled Choline Analogs, Patent No. [WO 2001/82864 A2, 200182864]
[8]  
DeGrado TR, 2001, CANCER RES, V61, P110
[9]  
DeGrado TR, 2001, J NUCL MED, V42, P1805
[10]   INHIBITORS OF CHOLINE TRANSPORT IN ALVEOLAR TYPE-II EPITHELIAL-CELLS [J].
DODIA, C ;
FISHER, AB ;
CHANDER, A ;
KLEINZELLER, A .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1992, 6 (04) :426-429